KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...

Shares of Protagonist Therapeutics PTGX moved up 14.0% on Thursday after management announced that it is entering into a worldwide license and collaboration agreement with Takeda TAK to develop ...

Check the time stamp on this data. Updated AI-Generated Signals for Protagonist Therapeutics Inc. (PTGX) available here: PTGX ...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product ...

Protagonist Therapeutics, Inc. (PTGX) stock price is 38.36 and Protagonist Therapeutics, Inc. (PTGX) 10-day simple moving average is 37.22. Protagonist Therapeutics, Inc. (PTGX) stock price is 38. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...